The link between lipids, statins and cancer: is there a role for cardio-oncology?
In human breast cancer specimens, CYP27A1 expression levels correlated with tumor grade(8). [...]lowering circulating cholesterol levels or interfering with its conversion to 27HC may provide a useful strategy to counteract breast cancer. While the data are interesting, several limitations of the st...
Gespeichert in:
Veröffentlicht in: | Future cardiology 2015-07, Vol.11 (4), p.389-393 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 393 |
---|---|
container_issue | 4 |
container_start_page | 389 |
container_title | Future cardiology |
container_volume | 11 |
creator | Jahangir, Eiman Polin, Nichole M Lavie, Carl J Fazio, Sergio |
description | In human breast cancer specimens, CYP27A1 expression levels correlated with tumor grade(8). [...]lowering circulating cholesterol levels or interfering with its conversion to 27HC may provide a useful strategy to counteract breast cancer. While the data are interesting, several limitations of the studies undermine their significance and applicability to the larger population, as most of the more convincing data are based on meta-analyses of small studies, and most of these are retrospective in nature. [...]limitations in data acquisition, unrecognized confounders and lack of true causality are at play. In addition to their cholesterol lowering effects, statins appear to have pleiotropic effects, such as inhibition of monocyte recruitment, antioxidant activity, immunomodulation and reduction in inflammatory response, all leading to proapoptotic, antiproliferative and anti-invasive states(13). [...]it is hypothesized that both by lowering lipid levels and through their pleiotropic effects, statins will reduce the risk of primary and recurrent cancer. [...]an increasing number of studies have described the protective benefit of statins on cancer incidence and recurrence, though several studies continue to show no relationship. |
doi_str_mv | 10.2217/FCA.15.32 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2507141233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A425228810</galeid><sourcerecordid>A425228810</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-ea900c6a2843ff24d128cd90a9416ea370263ac52e1e3304949c67b773b836573</originalsourceid><addsrcrecordid>eNptkVFLHDEQx4NUqrV98AtIoE-F7plMssnGFzmO2gqCFOxzyGVnNbqXnMkuxW_flNNKQeYhM5nffxLmT8gxZwsArk8vVssFbxcC9sgh11I2HZjuXc2lNo1SujsgH0q5Z0xow817cgAKhJGCH5KfN3dIxxAf6Bqn34ixFtvQl6-0TG4KsVAXe-pd9JjPaCh0usOM1NGcRqRDyrWX-5CaFH0a0-3T-UeyP7ix4Kfn84j8uvh2s_rRXF1_v1wtrxovQU0NOsOYVw46KYYBZM-h871hzkiu0AnNQAnnW0COQjBppPFKr7UW606oVosj8nk3d5vT44xlsvdpzrE-aaFlmksOQrxSt25EG-KQpuz8JhRvlxJagK7jrFKLN6gaPW6CTxGHUO__E3zZCXxOpWQc7DaHjctPljP71xNbPbG8tQIqe_L80Xm9wf4f-WJCBdodMMzTnLH4gHXddldVRfAh4huD_wDUnZSl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2507141233</pqid></control><display><type>article</type><title>The link between lipids, statins and cancer: is there a role for cardio-oncology?</title><source>MEDLINE</source><source>PubMed Central</source><creator>Jahangir, Eiman ; Polin, Nichole M ; Lavie, Carl J ; Fazio, Sergio</creator><creatorcontrib>Jahangir, Eiman ; Polin, Nichole M ; Lavie, Carl J ; Fazio, Sergio</creatorcontrib><description>In human breast cancer specimens, CYP27A1 expression levels correlated with tumor grade(8). [...]lowering circulating cholesterol levels or interfering with its conversion to 27HC may provide a useful strategy to counteract breast cancer. While the data are interesting, several limitations of the studies undermine their significance and applicability to the larger population, as most of the more convincing data are based on meta-analyses of small studies, and most of these are retrospective in nature. [...]limitations in data acquisition, unrecognized confounders and lack of true causality are at play. In addition to their cholesterol lowering effects, statins appear to have pleiotropic effects, such as inhibition of monocyte recruitment, antioxidant activity, immunomodulation and reduction in inflammatory response, all leading to proapoptotic, antiproliferative and anti-invasive states(13). [...]it is hypothesized that both by lowering lipid levels and through their pleiotropic effects, statins will reduce the risk of primary and recurrent cancer. [...]an increasing number of studies have described the protective benefit of statins on cancer incidence and recurrence, though several studies continue to show no relationship.</description><identifier>ISSN: 1479-6678</identifier><identifier>EISSN: 1744-8298</identifier><identifier>DOI: 10.2217/FCA.15.32</identifier><identifier>PMID: 26239431</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Breast cancer ; Cancer ; cardio-oncology ; Cardiovascular diseases ; cholesterol ; Health aspects ; HMG-CoA reductase inhibitors ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hyperlipidemias - complications ; Hyperlipidemias - drug therapy ; Lipids ; Mortality ; Neoplasms - epidemiology ; Risk factors ; Statins</subject><ispartof>Future cardiology, 2015-07, Vol.11 (4), p.389-393</ispartof><rights>Future Medicine Ltd</rights><rights>COPYRIGHT 2015 Future Medicine Ltd.</rights><rights>Copyright Future Medicine Ltd Jul 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-ea900c6a2843ff24d128cd90a9416ea370263ac52e1e3304949c67b773b836573</citedby><cites>FETCH-LOGICAL-c426t-ea900c6a2843ff24d128cd90a9416ea370263ac52e1e3304949c67b773b836573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26239431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jahangir, Eiman</creatorcontrib><creatorcontrib>Polin, Nichole M</creatorcontrib><creatorcontrib>Lavie, Carl J</creatorcontrib><creatorcontrib>Fazio, Sergio</creatorcontrib><title>The link between lipids, statins and cancer: is there a role for cardio-oncology?</title><title>Future cardiology</title><addtitle>Future Cardiol</addtitle><description>In human breast cancer specimens, CYP27A1 expression levels correlated with tumor grade(8). [...]lowering circulating cholesterol levels or interfering with its conversion to 27HC may provide a useful strategy to counteract breast cancer. While the data are interesting, several limitations of the studies undermine their significance and applicability to the larger population, as most of the more convincing data are based on meta-analyses of small studies, and most of these are retrospective in nature. [...]limitations in data acquisition, unrecognized confounders and lack of true causality are at play. In addition to their cholesterol lowering effects, statins appear to have pleiotropic effects, such as inhibition of monocyte recruitment, antioxidant activity, immunomodulation and reduction in inflammatory response, all leading to proapoptotic, antiproliferative and anti-invasive states(13). [...]it is hypothesized that both by lowering lipid levels and through their pleiotropic effects, statins will reduce the risk of primary and recurrent cancer. [...]an increasing number of studies have described the protective benefit of statins on cancer incidence and recurrence, though several studies continue to show no relationship.</description><subject>Breast cancer</subject><subject>Cancer</subject><subject>cardio-oncology</subject><subject>Cardiovascular diseases</subject><subject>cholesterol</subject><subject>Health aspects</subject><subject>HMG-CoA reductase inhibitors</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hyperlipidemias - complications</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Lipids</subject><subject>Mortality</subject><subject>Neoplasms - epidemiology</subject><subject>Risk factors</subject><subject>Statins</subject><issn>1479-6678</issn><issn>1744-8298</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkVFLHDEQx4NUqrV98AtIoE-F7plMssnGFzmO2gqCFOxzyGVnNbqXnMkuxW_flNNKQeYhM5nffxLmT8gxZwsArk8vVssFbxcC9sgh11I2HZjuXc2lNo1SujsgH0q5Z0xow817cgAKhJGCH5KfN3dIxxAf6Bqn34ixFtvQl6-0TG4KsVAXe-pd9JjPaCh0usOM1NGcRqRDyrWX-5CaFH0a0-3T-UeyP7ix4Kfn84j8uvh2s_rRXF1_v1wtrxovQU0NOsOYVw46KYYBZM-h871hzkiu0AnNQAnnW0COQjBppPFKr7UW606oVosj8nk3d5vT44xlsvdpzrE-aaFlmksOQrxSt25EG-KQpuz8JhRvlxJagK7jrFKLN6gaPW6CTxGHUO__E3zZCXxOpWQc7DaHjctPljP71xNbPbG8tQIqe_L80Xm9wf4f-WJCBdodMMzTnLH4gHXddldVRfAh4huD_wDUnZSl</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Jahangir, Eiman</creator><creator>Polin, Nichole M</creator><creator>Lavie, Carl J</creator><creator>Fazio, Sergio</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20150701</creationdate><title>The link between lipids, statins and cancer: is there a role for cardio-oncology?</title><author>Jahangir, Eiman ; Polin, Nichole M ; Lavie, Carl J ; Fazio, Sergio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-ea900c6a2843ff24d128cd90a9416ea370263ac52e1e3304949c67b773b836573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Breast cancer</topic><topic>Cancer</topic><topic>cardio-oncology</topic><topic>Cardiovascular diseases</topic><topic>cholesterol</topic><topic>Health aspects</topic><topic>HMG-CoA reductase inhibitors</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hyperlipidemias - complications</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Lipids</topic><topic>Mortality</topic><topic>Neoplasms - epidemiology</topic><topic>Risk factors</topic><topic>Statins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jahangir, Eiman</creatorcontrib><creatorcontrib>Polin, Nichole M</creatorcontrib><creatorcontrib>Lavie, Carl J</creatorcontrib><creatorcontrib>Fazio, Sergio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Future cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jahangir, Eiman</au><au>Polin, Nichole M</au><au>Lavie, Carl J</au><au>Fazio, Sergio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The link between lipids, statins and cancer: is there a role for cardio-oncology?</atitle><jtitle>Future cardiology</jtitle><addtitle>Future Cardiol</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>11</volume><issue>4</issue><spage>389</spage><epage>393</epage><pages>389-393</pages><issn>1479-6678</issn><eissn>1744-8298</eissn><abstract>In human breast cancer specimens, CYP27A1 expression levels correlated with tumor grade(8). [...]lowering circulating cholesterol levels or interfering with its conversion to 27HC may provide a useful strategy to counteract breast cancer. While the data are interesting, several limitations of the studies undermine their significance and applicability to the larger population, as most of the more convincing data are based on meta-analyses of small studies, and most of these are retrospective in nature. [...]limitations in data acquisition, unrecognized confounders and lack of true causality are at play. In addition to their cholesterol lowering effects, statins appear to have pleiotropic effects, such as inhibition of monocyte recruitment, antioxidant activity, immunomodulation and reduction in inflammatory response, all leading to proapoptotic, antiproliferative and anti-invasive states(13). [...]it is hypothesized that both by lowering lipid levels and through their pleiotropic effects, statins will reduce the risk of primary and recurrent cancer. [...]an increasing number of studies have described the protective benefit of statins on cancer incidence and recurrence, though several studies continue to show no relationship.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>26239431</pmid><doi>10.2217/FCA.15.32</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1479-6678 |
ispartof | Future cardiology, 2015-07, Vol.11 (4), p.389-393 |
issn | 1479-6678 1744-8298 |
language | eng |
recordid | cdi_proquest_journals_2507141233 |
source | MEDLINE; PubMed Central |
subjects | Breast cancer Cancer cardio-oncology Cardiovascular diseases cholesterol Health aspects HMG-CoA reductase inhibitors Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hyperlipidemias - complications Hyperlipidemias - drug therapy Lipids Mortality Neoplasms - epidemiology Risk factors Statins |
title | The link between lipids, statins and cancer: is there a role for cardio-oncology? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T04%3A18%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20link%20between%20lipids,%20statins%20and%20cancer:%20is%20there%20a%20role%20for%20cardio-oncology?&rft.jtitle=Future%20cardiology&rft.au=Jahangir,%20Eiman&rft.date=2015-07-01&rft.volume=11&rft.issue=4&rft.spage=389&rft.epage=393&rft.pages=389-393&rft.issn=1479-6678&rft.eissn=1744-8298&rft_id=info:doi/10.2217/FCA.15.32&rft_dat=%3Cgale_proqu%3EA425228810%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2507141233&rft_id=info:pmid/26239431&rft_galeid=A425228810&rfr_iscdi=true |